scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.CLGC.2019.11.016 |
P698 | PubMed publication ID | 32144046 |
P2093 | author name string | David F McDermott | |
Roger B Davis | |||
Wenxin Xu | |||
Brian Healy | |||
Andreas Varkaris | |||
P2860 | cites work | Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma | Q33383270 |
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 | ||
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. | Q52644831 | ||
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. | Q53470792 | ||
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. | Q54718176 | ||
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q62514960 | ||
Choosing Front-line Treatment for Metastatic Renal Cancer: Which Data Are Meaningful? | Q88865246 | ||
Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology | Q89074133 | ||
Radical shifts in the first-line management of metastatic renal cell carcinoma | Q90412378 | ||
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale | Q91249826 | ||
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human | Q91368102 | ||
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q91700806 | ||
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update | Q91900774 | ||
NCCN Guidelines Updates: Management of Metastatic Kidney Cancer | Q92217897 | ||
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma | Q92386877 | ||
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study | Q92399771 | ||
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma | Q92448726 | ||
Immunotherapy for renal cell carcinoma | Q92584185 | ||
The Changing Therapeutic Landscape of Metastatic Renal Cancer | Q92826118 | ||
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium | Q92844547 | ||
Towards individualized therapy for metastatic renal cell carcinoma | Q93139113 | ||
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review | Q93375175 | ||
P921 | main subject | renal cell carcinoma | Q1164529 |
metastatic renal cell carcinoma | Q19000948 | ||
P577 | publication date | 2019-12-05 | |
P1433 | published in | Clinical Genitourinary Cancer | Q332266 |
P1476 | title | Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma |
Search more.